{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:39:30Z","timestamp":1790203170992,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T00:00:00Z","timestamp":1461801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00259-016-3392-7","type":"journal-article","created":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T16:24:32Z","timestamp":1461860672000},"page":"1995-2004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study"],"prefix":"10.1007","volume":"43","author":[{"given":"Thibaut","family":"Cassou-Mounat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona","family":"Balogova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Nataf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Calzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Huchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaldoun","family":"Kerrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Devaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-No\u00ebl","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,28]]},"reference":[{"key":"3392_CR1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","volume":"23","author":"M Dimopoulos","year":"2009","unstructured":"Dimopoulos M, Terpos E, Comenzo RL, et al. International Myeloma Working Group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009;23:1545\u201356.","journal-title":"Leukemia"},{"key":"3392_CR2","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"3392_CR3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00259-011-1993-8","volume":"39","author":"T Derlin","year":"2012","unstructured":"Derlin T, Weber C, Habermann CR, et al. (18)F-FDG PET\/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39:493\u2013500.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3392_CR4","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989\u201395. Erratum in: Blood. 2012;120:2349.","journal-title":"Blood"},{"key":"3392_CR5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3324\/haematol.2015.124115","volume":"100","author":"EK Mai","year":"2015","unstructured":"Mai EK, Hielscher T, Kloth JK, et al. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica. 2015;100:818\u201325.","journal-title":"Haematologica"},{"key":"3392_CR6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cncr.24704","volume":"116","author":"S Ailawadhi","year":"2010","unstructured":"Ailawadhi S, Abdelhalim AN, Derby L, et al. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer. 2010;116:84\u201392.","journal-title":"Cancer"},{"key":"3392_CR7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0609.2010.01575.x","volume":"86","author":"BM Elliott","year":"2011","unstructured":"Elliott BM, Peti S, Osman K, et al. Combining FDG-PET\/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma. Eur J Haematol. 2011;86:289\u201398.","journal-title":"Eur J Haematol"},{"key":"3392_CR8","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","volume":"42","author":"BG Durie","year":"2006","unstructured":"Durie BG. The role of anatomic and functional staging in myeloma: description of Durie\/Salmon PLUS staging system. Eur J Cancer. 2006;42:1539\u201343.","journal-title":"Eur J Cancer"},{"key":"3392_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.semnuclmed.2014.08.002","volume":"45","author":"J Mihailovic","year":"2015","unstructured":"Mihailovic J, Goldsmith SJ. Multiple Myeloma: 18F-FDG-PET\/CT and diagnostic imaging. Semin Nucl Med. 2015;45:16\u201331.","journal-title":"Semin Nucl Med"},{"key":"3392_CR10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538\u201348.","journal-title":"Lancet Oncol"},{"key":"3392_CR11","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"3392_CR12","doi-asserted-by":"crossref","first-page":"908","DOI":"10.6004\/jnccn.2009.0061","volume":"7","author":"KC Anderson","year":"2009","unstructured":"Anderson KC, Alsina M, Bensinger W, et al. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009;7:908\u201342.","journal-title":"J Natl Compr Canc Netw"},{"key":"3392_CR13","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.ejrad.2014.09.012","volume":"83","author":"C Mesguich","year":"2014","unstructured":"Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. State of the art imaging of multiple myeloma: comparative review of FDG PET\/CT imaging in various clinical settings. Eur J Radiol. 2014;83:2203\u201323.","journal-title":"Eur J Radiol"},{"key":"3392_CR14","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3324\/haematol.2012.065359","volume":"97","author":"J Hillengass","year":"2012","unstructured":"Hillengass J, Ayyaz S, Kilk K, et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica. 2012;97:1757\u201360.","journal-title":"Haematologica"},{"key":"3392_CR15","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.7314\/APJCP.2014.15.22.9879","volume":"15","author":"WW Weng","year":"2014","unstructured":"Weng WW, Dong MJ, Zhang J, Yang J, Xu Q, Zhu YJ, et al. A systematic review of MRI, Scintigraphy, FDG-PET and PET\/CT for diagnosis of multiple myeloma related bone disease - Which is best? Asian Pac J Cancer Prev. 2014;15:9879\u201384.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3392_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00259-001-0711-3","volume":"29","author":"H Schirrmeister","year":"2002","unstructured":"Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:361\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3392_CR17","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","volume":"184","author":"MA Bredella","year":"2005","unstructured":"Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184:1199\u2013204.","journal-title":"AJR Am J Roentgenol"},{"key":"3392_CR18","first-page":"1457","volume":"43","author":"B Durie","year":"2002","unstructured":"Durie B, Waxman A, D\u2019Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43:1457\u201363.","journal-title":"J Nucl Med"},{"key":"3392_CR19","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1016\/j.ejrad.2012.06.028","volume":"81","author":"P Spinnato","year":"2012","unstructured":"Spinnato P, Bazzocchi A, Brioli A, et al. Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. Eur J Radiol. 2012;81:4013\u20138.","journal-title":"Eur J Radiol"},{"key":"3392_CR20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2214\/AJR.08.1633","volume":"192","author":"CP Shortt","year":"2009","unstructured":"Shortt CP, Gleeson TG, Breen KA, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009;192:980\u20136.","journal-title":"AJR Am J Roentgenol"},{"key":"3392_CR21","first-page":"40","volume":"12","author":"Z Yasar","year":"2015","unstructured":"Yasar Z, Acat M, Onaran H, Dincer HE, Cetinkaya E, Korkmaz AN. False-positive 18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET\/CT) scans mimicking malignancies. Med Glas (Zenica). 2015;12:40\u20136.","journal-title":"Med Glas (Zenica)"},{"key":"3392_CR22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1148\/radiol.2422051980","volume":"242","author":"A Dankerl","year":"2007","unstructured":"Dankerl A, Liebisch P, Glatting G, et al. Multiple myeloma: molecular imaging with 11C-methionine PET\/CT \u2013 initial experience. Radiology. 2007;242:498\u2013508.","journal-title":"Radiology"},{"key":"3392_CR23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00259-012-2333-3","volume":"40","author":"Y Nakamoto","year":"2013","unstructured":"Nakamoto Y, Kurihara K, Nishizawa M, et al. Clinical value of 11C-methionine PET\/CT in patients with plasma cell malignancy: comparison with 18F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2013;40:708\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3392_CR24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.113.131169","volume":"55","author":"CL Ho","year":"2014","unstructured":"Ho CL, Chen S, Leung YL, et al. 11C-Acetate PET\/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET\/CT. J Nucl Med. 2014;55:749\u201352.","journal-title":"J Nucl Med"},{"key":"3392_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00259-013-2520-x","volume":"41","author":"C Lin","year":"2014","unstructured":"Lin C, Ho CL, Ng SH, et al. (11)C-acetate as a new biomarker for PET\/CT in patients with multiple myeloma: initial staging and postinduction response assessment. Eur J Nucl Med Mol Imaging. 2014;41:41\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3392_CR26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","volume":"5","author":"C Nanni","year":"2007","unstructured":"Nanni C, Zamagni E, Cavo M, et al. 11C-choline vs. 18F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5:68.","journal-title":"World J Surg Oncol"},{"key":"3392_CR27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1078-0432.CCR-06-1357","volume":"13","author":"S Seo","year":"2007","unstructured":"Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427\u201333.","journal-title":"Clin Cancer Res"},{"key":"3392_CR28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00259-006-0164-9","volume":"33","author":"JN Talbot","year":"2006","unstructured":"Talbot JN, Gutman F, Fartoux L, et al. PET\/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3392_CR29","first-page":"110","volume":"61","author":"TR DeGrado","year":"2001","unstructured":"DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61:110\u20137.","journal-title":"Cancer Res"},{"key":"3392_CR30","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2967\/jnumed.110.075507","volume":"51","author":"JN Talbot","year":"2010","unstructured":"Talbot JN, Fartoux L, Balogova S, et al. Detection of hepatocellular carcinoma with PET\/CT: a prospective comparison of 18F-Fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51:1699\u2013706.","journal-title":"J Nucl Med"},{"key":"3392_CR31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/RLU.0000000000000303","volume":"39","author":"F Calabria","year":"2014","unstructured":"Calabria F, Chiaravalloti A, Schillaci O. 18F-Choline PET\/CT pitfalls in image interpretation. An update on 300 examined patients with prostate cancer. Clin Nucl Med. 2014;39:122\u201330.","journal-title":"Clin Nucl Med"},{"key":"3392_CR32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O\u2019Doherty MJ, Weber WA, et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181\u2013200.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3392_CR33","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376.","journal-title":"Blood"},{"key":"3392_CR34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11745-999-332-5","volume":"34","author":"T Sasagawa","year":"1999","unstructured":"Sasagawa T, Okita M, Murakami J, Kato T, Watanabe A. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids. 1999;34:17\u201321.","journal-title":"Lipids"},{"key":"3392_CR35","doi-asserted-by":"crossref","unstructured":"Vij R, Fowler KJ, Shokeen M. New approaches to molecular imaging of multiple myeloma. J Nucl Med. 2016;57:1\u20134.","DOI":"10.2967\/jnumed.115.163808"},{"key":"3392_CR36","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/RLU.0b013e318229208c","volume":"36","author":"C Xin","year":"2011","unstructured":"Xin C, Ruixue C, Fang L, Hongming Z. Lesions of multiple myeloma adjacent to the skull are better visualized on F-18 fluoroethyldimethyl-2-hydroxyethylammonium (FECH) PET images than on F-18 FDG PET images. Clin Nucl Med. 2011;36:912\u20134.","journal-title":"Clin Nucl Med"},{"key":"3392_CR37","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2169\/internalmedicine.50.5148","volume":"50","author":"H Machida","year":"2011","unstructured":"Machida H, Shinohara T, Hino H, et al. Immunoglobulin D-lambda type multiple myeloma presenting with FDG-PET\/CT negative bone marrow involvement. Intern Med. 2011;50:1483\u20137.","journal-title":"Intern Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3392-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3392-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3392-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T02:11:19Z","timestamp":1718503879000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3392-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,28]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["3392"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3392-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,28]]}}}